Novelos Inks Deal With Hong Kong-Based Lee’s Pharma For Cancer, Hepatitis Compounds
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novelos Therapeutics signed an exclusive license agreement with Hong Kong-based Lee's Pharmaceutical Dec. 17, with an aim to expand the sales of its cancer and hepatitis compounds - NOV-002 and NOV205 - in the Greater China region
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)